Chiesi organizes the 1st roundtable dedicated to the mission-oriented companies in the field of health & well-being

"Growth, Social Responsability, Healthcare": The mission-oriented companies' dynamic is on!

Chiesi is the 1st pharmaceutical laboratory engaged as a mission-oriented company. In France for 20 years, Chiesi is the only foreign family laboratory present across the entire added value chain: research and development, production and distribution, providing drugs to healthcare professionals and patients.

Bois-Colombes, April 15, 2021 - As a responsible health player, and a company aware about economic, environmental and societal issues, Chiesi is at the initiative of an exceptional institutional roundtable dedicated to mission-oriented companies in the field of healthcare. This event brings together two other mission-oriented companies, the impactful start-up Alenvi and the Rocher group, under the patronage of Olivia Grégoire, Ministry of State to the Economy, Finance and Recovery’s Minister, in charge of the Social, solidarity and responsible economy. This roundtable is taking place today at the Economy and Finances’ Ministry, and brings together various speakers: MP Coralie Dubost, rapporteur for the Pacte law, Marie Baumier, Director of relocation and recovery healthcare projects at the General Directorate of Enterprises, Charlotte Bouvard, Founding-Director of the patient association SOS Préma, Dr Eric Henry, President of the association “Care for Healthcare Professionals”, Pr. Bruno Housset, Breath Fondation's President and Emery Jacquillat, President of the Mission-oriented Companies Community. The debates are moderated by Cyrielle Hariel, journalist for BFM Business.

With its recent evolution as a mission-oriented company, Chiesi brings new energy. The laboratory is joining forces with other companies in this unique event with the ambition to initiate a virtuous dynamic, and to inspire other actors and entrepreneurs of health, and this, well beyond of the pharmaceutical sector.

The purpose of this event? Promote the important role of mission-oriented companies in the health and well-being sector and consider possible levers to amplify this approach and its impacts for the benefit of the community and patients. This publicized event brings together interested stakeholders: patient associations, academic societies, deputies and experts.

The session, introduced by Ministry of State Olivia Grégoire, reviews the progress and prospects of the Pacte law, two years after its promulgation.

It is followed by a first session of "crossed views" dedicated to the concrete commitments of three mission-oriented companies:

• The social company Alenvi whose mission is to promote the profession of caregiver, in order to guarantee quality support to all elderly people.

• The Rocher group, the first company with an international mission, creator of plant-based cosmetics, it notably owns the Arbonne, Petit Bateau and Yves Rocher brands. The group has just published the first international barometer to measure the impact of nature on peoples’ well-being.

• The European pharmaceutical laboratory Chiesi, committed to responsible innovation and ecological transition: it is the first company in the sector to choose to invest in the creation and manufacture of inhaled devices, such as aerosols-dosers, with a carbon footprint reduced by 90% - while maintaining the powder systems - in order to preserve the various possible therapeutic options for the benefit of patients with respiratory diseases.

After sharing these concrete actions undertaken by these mission-oriented companies, the second session of "external views" discussions focuses on the perceptions and expectations of the company's external stakeholders.

In this regard, the points of view of an association of patients (Charlotte Bouvard, SOS Préma), health professionals (Dc. Eric Henry, SPS; Pr. Bruno Housset, Fondation du Souffle), public authorities (Marie Baumier, DGE) and deputies (MP Coralie Dubost, rapporteur for the Pacte law), are highlighted.

Finally, Emery Jacquillat, as President of the Mission Business Community, opens the debate and brings new perspectives on the subject.

There is no doubt that this event will inspire other actors to join this dynamic, leading to concrete economic, environmental and societal actions, for the benefit of patients and people.

The patronage and the attendance of Olivia Grégoire confirm the relevance of the purpose.

Chiesi, who has made the choice to invest in France in a long-lasting and sustainable manner, is committed to it and wishes to mobilize other actors to join the movement.

About PACTE Law

At the instigation of the Economy, Finance and Recovery Minister, Bruno Lemaire, the PACTE law (Action Plan for Growth and Business Transformation) was promulgated in May 2019. This law gives levers to companies in order to innovate, transform, grow and create jobs. The PACTE law wishes to promote the policies in terms of social responsibility within companies through 3 levels:

For all companies: consideration of social and environmental issues is enshrined in law,

For voluntary companies:

• The integration of a (statutory) purpose to project oneself into its long-term environment
• The mission (statutory), with a more present commitment to results

About Chiesi Group

Based in Parma, Italy, Chiesi is an international research-focused pharmaceuticals and healthcare group with over 85 years’ experience, operating in 30 countries with more than 6,000 employees (Chiesi Group). To achieve its mission of improving people’s quality of life by acting responsibly towards society and the environment, the Group research, develops and markets innovative drugs in its three therapeutic areas: AIR (products and services that promote respiration, from new-born to adult populations), RARE (treatment for patients with rare and ultra-rare diseases) and CARE (products and services that support special care and consumer-facing self-care).

The Group’s Research and Development centre is based in Parma and works alongside 6 other important research and development centres in France, the U.S., Canada, China, the UK, and Sweden to promote its pre-clinical, clinical, and regulatory programmes.

Chiesi, since 2019, is the world’s largest B Corp certified pharmaceutical group. Chiesi Farmaceutici S.p.A. has changed in 2018 its legal status to a Benefit Corporation, by incorporating a double purpose for the creation of shared value, and to generate value for its business, for society and the environment. The global B Corp movement promotes business as a force for good. Moreover, as a Benefit Corporation, Chiesi Farmaceutici S.p.A. is required by law to include objectives of common benefit in its bylaws and to report annually in a transparent way. The Group is committed to becoming carbon neutral by the end of 2035.

For further information: www.chiesi.fr